title: Immune response to the mumps component of the MMR vaccine in the routine of immunisation services in the Brazilian National Immunisation Program.
abstract: A non-controlled longitudinal study was conducted to evaluate the combined vaccine against measles, mumps and rubella (MMR) immunogenicity in 150 children vaccinated in the routine of three health units in the city of Rio de Janeiro, Brazil, 2008-2009, without other vaccines administered during the period from 30 days before to 30 days after vaccination. A previous study conducted in Brazil in 2007, in 1,769 children ranging from 12-15 months of age vaccinated against yellow fever and MMR simultaneously or at intervals of 30 days or more between doses, had shown low seroconversion for mumps regardless of the interval between administration of the two vaccines. The current study showed 89.5% (95% confidence interval: 83.3; 94.0) seroconversion rate for mumps. All children seroconverted for measles and rubella. After revaccination, high antibody titres and seroconversion rates were achieved against mumps. The results of this study and others suggest that two MMR doses confer optimal immunoresponses for all three antigens and the possible need for additional doses should be studied taking into account not only serological, but also epidemiological data, as there is no serological correlate of protection for mumps.
authors.affiliation: Unidade de Assessoria Clínica, Bio-Manguinhos, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brasil.
authors.forename: Eliane Matos dos
authors.initials: EM
authors.lastname: Santos
authors.affiliation: Unidade de Assessoria Clínica, Bio-Manguinhos, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brasil.
authors.forename: Gloria Regina da
authors.initials: GR
authors.lastname: Silva e Sá
authors.affiliation: Laboratório de Vírus Respiratórios e Sarampo, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brasil.
authors.forename: Marilda Mendonça
authors.initials: MM
authors.lastname: Siqueira
authors.affiliation: Unidade de Assessoria Clínica, Bio-Manguinhos, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brasil.
authors.forename: Reinaldo de Menezes
authors.initials: Rde M
authors.lastname: Martins
authors.affiliation: Laboratório de Vírus Respiratórios e Sarampo, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brasil.
authors.forename: Luiz Antonio Bastos
authors.initials: LA
authors.lastname: Camacho
authors.affiliation: Unidade de Assessoria Clínica, Bio-Manguinhos, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brasil.
authors.forename: Vanessa dos Reis
authors.initials: Vdos R
authors.lastname: von Doellinger
authors.affiliation: Unidade de Assessoria Clínica, Bio-Manguinhos, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brasil.
authors.forename: Maria de Lourdes de Sousa
authors.initials: Mde L
authors.lastname: Maia
mesh_terms: D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology*; D001938:Brazil; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008137:Longitudinal Studies; D008297:Male; D008457:Measles / Q000276:immunology; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage / Q000276:immunology*; D009107:Mumps / Q000276:immunology* / Q000517:prevention & control; D012409:Rubella / Q000276:immunology; D000069078:Seroconversion
chemical_list: D000914:Antibodies, Viral; D022542:Measles-Mumps-Rubella Vaccine